Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 10/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19669278 | 0.98 | KDM4E (0.42) | CXCR4CXCL12RAD52KDM4EALDH1A1 | |
| SCHEMBL13602652 | 0.94 | CXCR4 (0.43) | CXCR4CXCL12RAD52KDM4EALDH1A1 | |
| SCHEMBL12391785 | 0.89 | GNAI3 (0.42) | CXCR4CXCL12KDM4EALDH1A1MEN1 | |
| SCHEMBL3645463 | 0.87 | RAD52 (0.44) | CXCR4CXCL12RAD52KDM4EALDH1A1 | |
| SCHEMBL13912964 | 0.85 | RAD52 (0.41) | CXCR4CXCL12RAD52KDM4EALDH1A1 | |
| SCHEMBL26748291 | 0.82 | GNAI3 (0.59) | RAD52KDM4EGNAI3GNAO1GNAI1 | |
| SCHEMBL19669160 | 0.82 | OPRL1 (0.40) | GNAI3GNAO1GNAI1 | |
| SCHEMBL12156771 | 0.80 | RAD52 (0.37) | CXCR4CXCL12RAD52KDM4EALDH1A1 | |
| SCHEMBL9417435 | 0.79 | CXCR4 (0.61) | CXCR4CXCL12RAD52KDM4EALDH1A1 | |
| SCHEMBL17733777 | 0.79 | CXCR4 (0.61) | CXCR4CXCL12RAD52KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4107198-A1 | POLYISOCYANATE PREPARATIONS | Covestro Deutschland AG (DE) | 2022-12-28 | — | — | EP | disclosed |
| US-8309552-B2 | Immunomodulating heterocyclic compounds | MEDIGENE AG (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8163757-B2 | Immuno inhibitory pyrazolone compounds | MEDIGENE AG (DE) | 2012-04-24 | — | — | US | disclosed |
| EP-2284172-A1 | Immunomodulating heterocyclic compounds | MediGene Ltd. (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-20100331342-A1 | Immuno Inhibitory Pyrazolone Compounds | MEDIGENE LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| US-7816361-B2 | Immuno inhibitory pyrazolone compounds | MEDIGENE LIMITED (GB) | 2010-10-19 | — | — | US | disclosed |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7598247-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070213345-A1 | Immuno Inhibitory Pyrazolone Compounds | AVIDEX LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213345-A1 | Immuno Inhibitory Pyrazolone Compounds | MSR1, CD40, CD4 | CXCR4 344/4885CXCL12 2425/4885RAD52 2128/4885 |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | CXCR4 4081/4885CXCL12 3456/4885RAD52 3635/4885 |
| US-20090312334-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | CXCR4 204/4885CXCL12 2240/4885RAD52 1638/4885 |
| US-20100331342-A1 | Immuno Inhibitory Pyrazolone Compounds | MSR1, CD40, CD4 | CXCR4 371/4885CXCL12 2807/4885RAD52 2136/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | CXCR4 204/4885CXCL12 2240/4885RAD52 1638/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | CXCR4 185/4885CXCL12 2169/4885RAD52 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.